The facility is located in Buildings 1, 10, 60, 600, 601 and the Colin Watson Aerosol Layout (CWAL) and associated minor structures, all co-located with Canadian Forces Base Suffield near the village of Ralston, Alberta, Canada.
4. 每一设施的组织结构：
(二) 人员按军职和文职分列：
(三) 人员按工作性质分列：
Bacteriology Immunology
Microbiology Virology
Chemistry Biochemistry
Biotechnology Veterinary Medicine
Medicine Pharmacology
The research in this facility is primarily funded by the Departments of National Defence and Public Safety Canada and under contract to, or through collaborative agreements, with other government departments and industry.
Funding level estimates (including salaries): $5,760,9215
(七) 下列方案领域的供资水平：
All staff members are encouraged to publish the results of their research in the open literature whenever not precluded by security or intellectual property considerations. There is also an internal publication system which is used for publications regardless of content.
Bader D, Garrecht B, Rowsell S. Identification of biothreat agents in powders and other interferent matrices using the FilmArray® biosurveillance system. DRDC-RDDC-2018-R177.
Bader D, Fisher G, and Rowsell S. Genetic confirmation of DRDC – Suffield Research Centre biological field simulants for the New Substances Notification Program, DRDC-RDDC-2018-R144.
Bader D, Garrecht B. Detection of B. anthracis genetic markers in naturally occurring spore-positive soils using the FilmArray® biosurveillance system. Tracking# R18-1210-01239_PA-EC
Buteau, S and Nadeau, D., Laboratory Benchtop Bioaerosol Chamber version 2 – Design, optimization, results (U), DRDC-RDDC-2018-R137, May 2018, PROTECTED A (EXPORT CONTROLLED)
Buteau, S. and Nadeau, D., Biological Threat Detection Identification and Monitoring (Bio DIM) suite deployment at Dugway Proving Ground (DPG) 2017 (U), DRDC-RDDC-2018- L161 to Defence Joint CBRN Directorate, July 2018, PROTECTED A (EXPORT CONTROLLED).
Buteau, S. and , Bouffard, F, Enhancing situational awareness by combining multiple point and standoff sensor technologies (U), Proceeding for the NBC 2018 – 10th symposium on CBRNE threats, Rovaniemi, Finland, DRDC-RDDC-E18-0320-1001, 5 June 2018, 5 pages, UNCLASSIFIED.
Chan N, Lee W, Rowsell S. Scientific review of work progress on pathogen detection DNA biosensor for water monitoring. DRDC-RDDC-2018-L172.
Evans DH and Noyce R. University of Alberta. Vaccinia vaccine review. Contract Report, May 2018, DRDC-RDDC-2018-C069.
Forbes K. Validation of CBRN Surveillance Information Requirements. DRDC-RDDC-2018-C162.
Hayward S. A novel diagnostic platform for project consideration. DRDC-RDDC-2018-L171.
Hayward S. Evaluation of solid phase media for sampling of biological material for downstream immune–based detection and identification. R18-0919-00795.
Hu W, Steigerwald R, Kalla M, Volkmann A, Noll D. Protective efficacy of monvalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses. Vaccine June 2018.
Nagata L, Irwin CR, Hu W, Evans DH. Vaccinia vaccines to biothreat and emerging viruses. Biotech. Gen. Eng. Rev. Apr-18.
Sheibani S, Chan N. Protein-nucleic acid (receptor-ligand) binding detection techniques. DRDC-RDDC-2018-R027.
Stratilo C. Proposed research in antibacterials for the Medical Countermeasures Project fiscal year (FY) 2019-2024. DRDC-RDDC-2018-L182.
Stratilo C, Jager S, Swayze R. Identification of a novel virulence factor of Burkholderia pseudomallei and B. mallei, a protective vaccine antigen against melioidosis. DRDC-RDDC-2018-R189.
Stratilo C, Gubala A, O’Connor K, Taylor J, Despeyroux D, Mitchell I, Yousef J, Ford B, Piggot T, Messer A. Incremental approach to achieving an Operating Capability for an in-theatre High Confidence Biological Identification Capability Tracking# E18-0918-00793.
Stratilo, C.W., Gubala, A., O’Connor, K., Taylor, J., Despeyroux, D., Evaluation of EDGE Platform by CBR Mou Inform Task 3. CBR MOU-IWG-3-2018-02. E18-0404-00022, 2018, 18 pages.
Wang M. Cytokine storm mitigation. DRDC-RDDC-2018-C131.
Wishart DS. Evaluation of bioinformatics platforms. DRDC-RDDC-2018-C110.
Wu J, Hu W, Nagata L, Rowsell S. Proposed way ahead for novel medical countermeasure technology platforms against viral threats. DRDC-RDDC-2018-L122.
Funding estimate stated in (vii) is the total estimate of funding levels for research, development and test and evaluation collectively.
Assessment of the hazards from biological agents and toxins involves research to understand the dispersion of such agents and is carried out by mathematical modelling techniques. Part of the work in detection involves R&D leading to the production of field portable biological agent detection systems. In medical countermeasures, research is carried out on new drugs and vaccines, for example humanized antibodies, antivirals, antibiotics and vaccines. Microorganisms other than Newcastle disease virus (NDV) and Bacillus atrophaeus (formerly Bacillus globigii (BG) which have been used in the biological defence program are Bacillus anthracis, Brucella species (abortus, melitensis, neotomae, ovis and suis), Burkholderia species (mallei, pseudomallei) Francisella tularensis, Mycobacterium tuberculosis, Yersinia enterocolitica, Yersinia pestis, various influenza virus strains, western equine encephalitis, eastern equine encephalitis, Venezuelan equine encephalitis, Highlands J virus, Sindbis virus and dengue virus (serotypes 1-4). Toxins used include botulinum toxin, staphylococcal enterotoxin B and ricin. In the early to mid-1980s, outdoor studies have involved only NDV middle through 1980’s and BG. Currently, outdoor studies use BG as well as Male-specific Coliphage 2 and Pantoea agglomerans (formerly Erwinia herbicola).
(9) 包括病毒和朊粒。